Related Experiment Videos
Chlorambucil dosage in frequently relapsing nephrotic syndrome: a controlled clinical trial
Insights
A stable chlorambucil dose is as effective as increasing doses for treating frequently relapsing nephrotic syndrome in children. This finding offers a simpler, potentially safer treatment option for pediatric nephrotic syndrome management.
Area of Science:
- Pediatric Nephrology
- Clinical Pharmacology
- Immunosuppressive Therapy
Background:
- Frequently relapsing nephrotic syndrome (FRNS) in children often requires long-term immunosuppressive therapy.
- Chlorambucil is an alkylating agent used in FRNS, but optimal dosing strategies remain under investigation.
- Prednisone is a standard adjunctive therapy for FRNS.
Purpose of the Study:
- To compare the efficacy and safety of two chlorambucil dosage regimens in children with FRNS.
- To evaluate long-term remission rates and infectious complications associated with stable versus increasing chlorambucil doses.
Main Methods:
- A controlled clinical trial involving 21 children with FRNS.
- Group I (n=10): Stable chlorambucil dose (0.2 mg/kg/day) for 56–60 days.
- Group II (n=11): Increasing chlorambucil dose (0.2–0.63 mg/kg/day) for 42–77 days.
- All patients received concurrent alternate-day prednisone (60 mg/m²).
Main Results:
- Relapse rates were similar in both groups, with two children in each group relapsing.
- Long-term follow-up averaged 28.6 months (Group I) and 27.2 months (Group II).
- Three children in the increasing dose group (Group II) experienced infectious complications.
Conclusions:
- A stable dosage regimen of chlorambucil is as effective as an increasing dose regimen for achieving long-term remission in pediatric FRNS.
- The stable dose regimen may offer a potentially safer alternative due to fewer infectious complications observed.
- These findings support the use of a stable chlorambucil dosing strategy in managing frequently relapsing nephrotic syndrome in children.
Abstract:
A controlled clinical trial was performed using two dosage regimens of chlorambucil to treat children with frequently relapsing nephrotic syndrome. All children concurrently received prednisone (60 mg/m2 on alternate days). Ten children (Group I) were given chlorambucil as a stable dose (0.2 mg/kg/day) for 56 to 60 days, and 11 children (Group II) received increasing doses (0.2 to 0.63 mg/kg/day) for 42 to 77 days. Two children in each group subsequently relapsed. Follow-up averaged 28.6 and 27.2 months in Groups I and II, respectively. Three children in Group II developed infectious complications. The data indicate that a stable dosage regimen for chlorambucil is as effective as an increasing dose regimen in achieving long-term remission of frequently relapsing nephrotic syndrome.